{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:43:50Z","timestamp":1769849030731,"version":"3.49.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["2018YFC0114600"],"award-info":[{"award-number":["2018YFC0114600"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170547 81873558"],"award-info":[{"award-number":["82170547 81873558"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Nonspecific terminal ileal ulcers are one of the common ulcerative diseases in terminal ileum. However, the studies about treatment efficacy are scarce. We aimed to investigate the efficacy of mesalazine in the treatment of this disease.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Eighty-two patients with nonspecific terminal ileal ulcers who sought outpatient medical treatment in the Division of Gastroenterology, Wuhan Union Hospital, from April 2016 to January 2019 were enrolled and randomly divided into two groups. The experimental group took mesalazine orally, 4.0\u00a0g\/d, once a day for 3\u00a0months. The control group was followed up without special intervention. The primary endpoint was the endoscopic remission rate at the 6<jats:sup>th<\/jats:sup> and 12<jats:sup>th<\/jats:sup> month. Secondary endpoints included the clinical remission rate at the 1<jats:sup>st<\/jats:sup>, 6<jats:sup>th<\/jats:sup> and 12<jats:sup>th<\/jats:sup> month and adverse events (ChiCTR1900027503).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> About the endoscopic efficacy, the remission rate of the experimental group and control group was 73.2 versus 61.0% at the 6<jats:sup>th<\/jats:sup> month (RR = 1.20, 95%CI 0.88\u223c1.63, <jats:italic>p<\/jats:italic> = 0.24) and 87.8 versus 78.0% at the 12<jats:sup>th<\/jats:sup> month (RR = 1.13, 95%CI 0.92\u223c1.37, <jats:italic>p<\/jats:italic> = 0.24). About the clinical efficacy, the remission rate was 70.3 versus 43.8% at the 1<jats:sup>st<\/jats:sup> month (RR = 1.61, 95%CI 1.03\u223c2.51, <jats:italic>p<\/jats:italic> = 0.03), 83.8 versus 68.8% at the 6<jats:sup>th<\/jats:sup> month (RR = 1.22, 95%CI 0.93\u223c1.60, <jats:italic>p<\/jats:italic> = 0.14) and 91.9 versus 81.3% at the 12<jats:sup>th<\/jats:sup> month (RR = 1.13, 95%CI 0.93\u223c1.37, <jats:italic>p<\/jats:italic> = 0.34). During follow-up, no patients were diagnosed with Crohn\u2019s disease or intestinal tuberculosis, and no patients developed significant complications.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> For patients with nonspecific terminal ileal ulcers, there is no disease progression over a short term. In addition, there is no significant difference in clinical or endoscopic efficacy between patients who received mesalazine and patients who are followed up without special intervention.<\/jats:p>","DOI":"10.3389\/fphar.2022.989654","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T11:37:01Z","timestamp":1663933021000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The efficacy of mesalazine on nonspecific terminal ileal ulcers: A randomized controlled trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Junrong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangmei","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinfang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yidong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangru","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s10787-021-00856-1","article-title":"A review of the biological and pharmacological activities of mesalazine or 5-aminosalicylic acid (5-ASA): An anti-ulcer and anti-oxidant drug","volume":"29","author":"Beiranvand","year":"2021","journal-title":"Inflammopharmacology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"173573","DOI":"10.1016\/j.ejphar.2020.173573","article-title":"Ameliorating and protective effects mesalazine on ethanol-induced gastric ulcers in experimental rats","volume":"888","author":"Beiranvand","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.gtc.2020.07.002","article-title":"Mesalamine in the initial therapy of ulcerative colitis","volume":"49","author":"Chibbar","year":"2020","journal-title":"Gastroenterol. Clin. North Am."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1097\/PAS.0b013e3181ad25b6","article-title":"Isolated asymptomatic ileitis does not progress to overt Crohn disease on long-term follow-up despite features of chronicity in ileal biopsies","volume":"33","author":"Courville","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2147\/DDDT.S95316","article-title":"Randomized clinical trial: Pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis","volume":"10","author":"Cuffari","year":"2016","journal-title":"Drug Des. devel. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.03069.x","article-title":"Review article: Mode of action and delivery of 5-aminosalicylic acid - new evidence","volume":"24","author":"Desreumaux","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11894-010-0112-5","article-title":"Ileitis: When it is not Crohn's disease","volume":"12","author":"Dilauro","year":"2010","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14740\/gr698w","article-title":"Facing terminal ileitis: Going beyond Crohn's disease","volume":"9","author":"Goulart","year":"2016","journal-title":"Gastroenterol. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/01.mcg.0000210104.59370.66","article-title":"Asymptomatic ileitis: Past, present, and future","volume":"40","author":"Greaves","year":"2006","journal-title":"J. Clin. Gastroenterol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1440-1746.2007.05151.x","article-title":"Diagnostic value of terminal ileum intubation during colonoscopy","volume":"23","author":"Jeong","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11938-001-0043-1","article-title":"Small bowel ulcers","volume":"4","author":"Karnam","year":"2001","journal-title":"Curr. Treat. Options Gastroenterol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/1751-2980.12307","article-title":"Frequency, natural course and clinical significance of symptomatic terminal ileitis","volume":"17","author":"Kedia","year":"2016","journal-title":"J. Dig. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1007\/s10620-020-06781-7","article-title":"Clinical course of terminal ileal ulcers observed incidentally during colonoscopy.","volume":"66","author":"Kim","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1055\/s-0031-1299685","article-title":"The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid)","volume":"62","author":"Klotz","year":"2012","journal-title":"Arzneimittelforschung."},{"key":"B15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1365-2036.2009.04195.x","article-title":"Systematic review: Molecular chemoprevention of colorectal malignancy by mesalazine","volume":"31","author":"Lyakhovich","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1111\/j.1572-0241.2000.03342.x","article-title":"Progress in understanding the mechanisms of action of 5-aminosalicylic acid","volume":"95","author":"MacDermott","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"E539","DOI":"10.1055\/s-0043-100688","article-title":"Symptomatic isolated terminal ileal ulcers: Etiology and clinical significance","volume":"5","author":"Mehta","year":"2017","journal-title":"Endosc. Int. Open"},{"key":"B18","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3748\/wjg.v19.i6.889","article-title":"Mucosal healing effect of mesalazine granules in naproxen-induced small bowel enteropathy","volume":"19","author":"R\u00e1cz","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/apt.14688","article-title":"Systematic review: Safety of mesalazine in ulcerative colitis","volume":"47","author":"Sehgal","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.5152\/UCD.2015.2756","article-title":"Diagnostic value of terminal ileum biopsies in patients with abnormal terminal ileum mucosal appearance","volume":"31","author":"Velidedeo\u011flu","year":"2015","journal-title":"Ulus. Cerrahi Derg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1471-230X-11-51","article-title":"Long-term follow-up of nonspecific small bowel ulcers with a benign course and no requirement for surgery: Is this a distinct group?","volume":"11","author":"Wang","year":"2011","journal-title":"BMC Gastroenterol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"8838613","DOI":"10.1155\/2020\/8838613","article-title":"Analysis and follow up of endoscopy results in 1099 patients with terminal ileum lesions","volume":"2020","author":"Zhong","year":"2020","journal-title":"Can. J. Gastroenterol. Hepatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.989654\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T11:37:03Z","timestamp":1663933023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.989654\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":22,"alternative-id":["10.3389\/fphar.2022.989654"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.989654","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"article-number":"989654"}}